January 1, 1970 (Vol. , No. )
John Sterling Editor in Chief Genetic Engineering & Biotechnology News
Orthopedic surgery, as we know it, is undergoing a revolution. Saws, hammers, screws, pins, and metal rods are beginning to give way to growth factors, stem cells, gene therapy, and tissue engineered products. In other words, molecular medicine ultimately will transform orthopedic surgery.
One of leaders at the forefront of this paradigm shift is Dr. Thomas Einhorn, chairman of the department of orthopedic surgery and professor of orthopedic surgery, biochemistry, and biomedical engineering at Boston University.
During this week’s GEN podcast, Dr. Einhorn talks about how the increasing use of biologics is changing the practice of surgery. He discusses some of the major advantages that biologics such as recombinant proteins enjoy over standard surgical tools. Dr. Einhorn provides current examples of where biologics are already having an impact in surgical procedures, including those he has carried out himself.
Dr. Einhorn also goes over the key obstacles biologic-related approaches must overcome before they become more common in operating rooms. He also looks at those biologic techniques that appear to be most promising long-term.
